NASDAQ · VTRS
Viatris Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for VTRS: Nov 05, 2026
Viatris Inc. Common Stock is expected to report earnings on 11/05/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $0.64. The reported EPS for the same quarter last year was $0.67.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.64 | $0.66 | $0.62 | 5 |
| Dec 2026 | $0.60 | $0.64 | $0.56 | 4 |
| Mar 2027 | $0.64 | $0.71 | $0.59 | 3 |
| Jun 2027 | $0.71 | $0.73 | $0.69 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · BNK Invest · The Motley Fool- Zacks · Oct 29, 9:00 AM EDTViatris (VTRS) Expected to Beat Earnings Estimates: Should You Buy?Viatris (VTRS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 27, 11:10 AM EDTWill Viatris (VTRS) Beat Estimates Again in Its Next Earnings Report?Viatris (VTRS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Zacks · Oct 26, 8:50 AM EDTWhy Viatris (VTRS) is a Top Momentum Stock for the Long-TermWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- RTTNews · Oct 23, 10:53 AM EDTWeekly Buzz: AZN, ALVO Score FDA Nod; EYPT Cuts Jobs; RHHBY, GEHC Enter Deal; VERA Posts Trial Win(RTTNews) – Healthcare and biotech news this week centred on regulatory approvals, strategic deals, and pivotal clinical data.
- Zacks · Oct 20, 8:40 AM EDTHere's Why Viatris (VTRS) is a Strong Value StockWondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
- RTTNews · Oct 16, 9:55 PM EDTFDA Approves Viatris' RYZUMVI For Presbyopia Treatment(RTTNews) – Viatris Inc. (VTRS) announced that the U.S. Food and Drug Administration approved RYZUMVI (phentolamine ophthalmic solution 0.75%) for the treatment of presbyopia in adults.
- BNK Invest · Oct 14, 4:47 PM EDTDow Takes Over #374 Spot From ViatrisIn the latest look at the underlying components of the S&P 500 ordered by largest market capitalization, Dow Inc (Symbol: DOW) has taken over the #374 spot from Viatris Inc (Symbol: VTRS), according to The Online Investor. Market capitalization is an important data point
- Zacks · Oct 9, 9:37 AM EDTViatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain PortfolioVTRS is set to acquire PCRX for $1.65 billion in cash, adding two marketed pain therapies and a clinical-stage gene therapy candidate to expand its non-opioid pain portfolio.
- RTTNews · Oct 9, 6:29 AM EDTBiotech Stocks At 52-Week Highs – PCRX +44% On Acquisition News; MANE+14%, HAE+17%, CON, HSTM(RTTNews) – The following biotech stocks reached a 52-week high on October 8, 2026, driven by catalysts such as reports of an upcoming acquisition or upcoming financial reports.
- The Motley Fool · Oct 8, 11:33 AM EDTWhy Pacira BioSciences Skyrocketed TodayPacira BioSciences is being bought out by Viatrias.
- RTTNews · Oct 8, 8:34 AM EDTViatris Agrees To Acquire Pacira BioSciences In $1.65 Bln Cash Deal(RTTNews) – Thursday, Viatris Inc. (VTRS) announced an agreement to acquire all of the outstanding shares of common stock of Pacira BioSciences, Inc. (PCRX), a biopharmaceutical company focusing on innovative non-opioid pain therapies, for $36.50 per share in a cash deal.
- Zacks · Oct 6, 10:40 AM EDTVTRS vs. AVTR: Which Stock Is the Better Value Option?VTRS vs. AVTR: Which Stock Is the Better Value Option?
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Viatris Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.